CD4 and rheumatoid arthritis: In this study, MSCs and DMARDs were co-administrated intravenously in 172 patients with active RA inducing a significant increase in the percentage of regulatory CD4+ T cells (Treg) in the blood together with a significant clinical improvement for up to 6 months.